Abeona Therapeutics (ABEO) Income towards Parent Company (2011 - 2026)

Abeona Therapeutics' Income towards Parent Company history runs 16 years deep, the most recent figure standing at -$17.1 million for Q1 2026.

• In Q1 2026, Income towards Parent Company fell 41.95% year-over-year to -$17.1 million; the TTM figure through Mar 2026 stood at $66.8 million (up 253.49% YoY), while the FY2025 annual figure was $56.3 million, up 189.31% from the prior year.
• Income towards Parent Company for Q1 2026 stood at -$17.1 million, up from -$35.3 million in the prior quarter.
• The five-year high for Income towards Parent Company was $124.3 million in Q2 2025, with the low at -$35.3 million in Q4 2025.
• The 5-year median for Income towards Parent Company is -$13.1 million (2022), against an average of -$7.4 million.
• Peak annual rise in Income towards Parent Company reached 1578.98% in 2025, while the deepest fall reached 310.15% in 2025.
• Abeona Therapeutics' Income towards Parent Company stood at -$13.1 million in 2022, then dropped by 1.56% to -$13.3 million in 2023, then surged by 35.32% to -$8.6 million in 2024, then tumbled by 310.15% to -$35.3 million in 2025, then jumped by 51.67% to -$17.1 million in 2026.
• Business Quant data shows ABEO's Income towards Parent Company at -$17.1 million in Q1 2026, -$35.3 million in Q4 2025, and -$5.2 million in Q3 2025.